Retour

INVENTIVA (EPA:IVA) Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor

Directive transparence : information réglementée

06/12/2021 22:00

20/05/2022 22:00

Results of the votes of the Combined Shareholders’ Meeting of May 19,...

19/05/2022 22:00

Description of the Share Repurchase Program Authorised by the Ordinary...

16/05/2022 22:00

Inventiva reports 2022 First Quarter Financial Information and provides...

16/05/2022 08:00

Inventiva secures a €50 million credit facility from the European...

07/04/2022 22:00

Inventiva announces the presentation of a scientific abstract at the next...

11/03/2022 22:44

Inventiva announces filing of its 2021 Universal Registration Document and...

07/03/2022 22:26

Inventiva reports its 2021 Full-Year Results: key milestones achieved with...

07/03/2022 22:00

Inventiva publie ses résultats annuels 2021 : Avancées majeures avec...

01/03/2022 22:00

Inventiva announces participation at several conferences in March 2022

14/02/2022 22:00

Inventiva reports cash position and revenues for Full-Year 2021

Voir tous les communiqués de INVENTIVA